



FOR IMMEDIATE RELEASE

Veeva Vault RIM Driving Greater Speed and Compliance for More Than 350 Life Sciences Organizations

Fast-growing biotechs and 15 of the top 20 pharma companies are accelerating modernization to streamline regulatory submissions on a single, unified platform

BARCELONA, Spain — 4 Oct. 2022 — Veeva Systems (NYSE: VEEV) today announced that more than 350 companies are transforming regulatory operations with [Veeva Vault RIM Suite](#) applications to speed execution and keep pace with evolving health authority requirements. A growing number of emerging biotechs are adopting Veeva regulatory applications, including more than 65 companies over the last year, to scale operations and simplify submission planning, development, publishing, and archiving.

"The rate of change across requirements and regulatory environments calls for agile systems that can adapt quickly," said Marc Gabriel, vice president, Veeva Vault RIM. "More companies are relying on Veeva Vault RIM innovations to keep pace with regional and local regulations, and we're proud to support the industry as a trusted partner for advanced regulatory information management."

Veeva continues to deliver advancements that help customers streamline global regulatory processes. New features added to Vault RIM include:

- Active Dossier to manage chemistry, manufacturing, and controls (CMC) documents in effect for a given product and market
- Label change tracking across products
- Seamless connection with [Veeva Vault PromoMats](#) to send 2253-based submissions to Vault RIM
- Non-eCTD electronic publishing to meet global submission requirements

"Establishing one source for information was a top priority at Mundipharma. Veeva Vault RIM has allowed us to consolidate data and documents from many different sources for greater visibility and efficiency," said Helen Donnelly, head of regulatory operations at Mundipharma.

"Leveraging Veeva's advanced capabilities across our regulatory operations has helped to significantly simplify our processes, including nearly a 35% reduction in process handovers."

A top 20 pharma used Vault RIM to harmonize more than 19 million data points and unify over 65 legacy systems onto a single cloud platform. The modernization effort helped to reduce SOPs and work instructions by over 90%, improving overall speed and agility.

Vault RIM is also enabling companies with end-to-end submission development for faster time to market. More than 50 companies are using [Veeva Vault Submissions Publishing](#) to simplify and accelerate the submission process with assisted submission building and automated rendering of documents under existing standards.

The Vault RIM Suite includes [Vault Registrations](#), [Vault Submissions](#), Vault Submissions Publishing, and [Vault Submissions Archive](#) for unified RIM capabilities on one cloud platform. Vault RIM is part of [Veeva Development Cloud](#), a unified suite of applications for clinical, regulatory, quality, and safety to help organizations drive business processes across R&D and manufacturing.

Learn how companies are accelerating regulatory submissions at [Veeva R&D and Quality Summit](#). Life sciences industry professionals can [register](#) for the Oct. 19-20 in-person event in Boston.

Additional Information

For more on Veeva Vault RIM Suite, visit: veeva.com/eu/VaultRIM
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veeva_eu on Twitter: twitter.com/veeva_eu

About Veeva Systems

Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com/eu.

Veeva Forward-looking Statements

This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended July 31, 2022, which you can find [here](#) (a summary of risks which may impact our business can be found on pages 39 and 40), and in our subsequent SEC filings, which you can access at sec.gov.

###

Contact:

Jeremy Whittaker
Veeva Systems
+49-695-095-5486
jeremy.whittaker@veeva.com

Deivis Mercado
Veeva Systems
925-226-8821
deivis.mercado@veeva.com